AMRN News 1.41 06/02/2014 04:26:05 Amarin Corporation Plc (A

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarin Corporation Plc (AMRN) 1.41 $AMRN

Amarin to Present at the Jefferies 2014 Global Healthcare Conference
Marketwire - Thu May 29, 7:03AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014, at 8:00 a.m. ET.

High Triglyceridemia Therapeutics Pipeline Review 2014 - 16 Companies & 19 Drug Profiles
M2 - Tue May 20, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bkl7cl/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Tekmira Pharmaceuticals Corp. - Actavis plc - Isis Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Amarin Corporation plc - Alnylam Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cardax Pharmaceuticals, Inc. - Essentialis, Inc. - Epax AS - Pharmena SA - FORMAC Pharmaceuticals N.V. - Omthera Pharmaceuticals, Inc. - Poxel SA - Acasti Pharma Inc. Drug Profiles - icosapent ethyl - omega-3-carboxylic acids - diazoxide CR - AKR-963 - TRIA-662 - ISIS-APOCIIIRx - NKPL-66 - pradigastat sodium - CAT-2003 - fenofibrate - bezafibrate ER - CDX-085 - CAT-2000 Series - AS-1708727 - MAT-9001 - Drug For Hypertriglyceridemia - ALN-ANG - Small Molecule Farnesoid X Receptor Agonist for Gastrointestinal, Metabolic and Cardiovascular Diseases - Peptides for Dyslipidemic and Vascular Disorders For more information visit http://www.researchandmarkets.com/research/bkl7cl/high

AstraZeneca's Fishy FDA Approval
Brian Orelli, The Motley Fool - Motley Fool - Mon May 19, 5:28PM CDT
The Food and Drug Administration recently approved AstraZeneca 's Epanova, adding it to the growing list of omega-3 fish oil drugs that includes GlaxoSmithKline 's Lovaza and Amarin 's Vascepa. In the following video, senior biotech...

Ligand-AstraZeneca Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 5:00PM CDT
Ligand Pharmaceuticals Inc. (LGND) and AstraZeneca signed a licensing and research deal.

Technical Pulse on Active Equities -- Research on Amarin, Abbott Laboratories, Apple, and T-MobileUS
PR Newswire - Fri May 16, 9:23AM CDT
The trading session on Thursday, May 15, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,446.81, down 1.01% and the NASDAQ Composite closed at 4,069.29, down 0.76%. The S&P 500 finished the day 0.94% lower at 1,870.85. The losses were broad based as nine out of ten sectors finished on a negative note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Amarin Corp. PLC (NASDAQ: AMRN), Abbott Laboratories (NYSE: ABT), Apple Inc. (NASDAQ: AAPL) and T-Mobile US Inc. (NYSE: TMUS). Free technical research on AMRN, ABT, AAPL and TMUS can be downloaded upon signing up at:

Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Thu May 15, 1:37PM CDT
Amarin (AMRN) is down big after announcing private exchange transaction of outstanding senior notes.

Why Amarin Corporation PLC Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Thu May 15, 12:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin , a biopharmaceutical company...

Amarin Down 8.6%, Shares Slide into the Red (AMRN)
Comtex SmarTrend(R) - Thu May 15, 10:09AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 8.6% to $1.39 on 1.4x average daily volume. Thus far today, Amarin has traded 2.4 million shares, vs. average volume of 1.7 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.9%) and underperformed the S&P 500 (-8.6% to the S&P's -1.0%) during today's trading.

Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes
GlobeNewswire - Thu May 15, 5:19AM CDT
Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" , announced today that it and its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer" , have entered into separate, privately negotiated exchange agreements with certain holders of its outstanding 3.50% Exchangeable Senior Notes due 2032 issued on January 9, 2012 (the "2012 Notes" pursuant to which the Issuer will exchange $118.734 million in aggregate principal amount of the 2012 Notes for $118.734 million in aggregate principal amount of new 3.50% May 2014 Exchangeable Senior Notes due 2032 (the "2014 Notes" . Following the closing of these transactions, $31.266 million in aggregate principal amount of the 2012 Notes will remain outstanding with terms unchanged. The 2014 Notes will be exchangeable into American Depositary Shares of Amarin ("ADSs" at the option of the holders at an initial exchange rate of 384.6154 ADSs per $1,000 principal amount of 2014 Notes (equivalent to an initial exchange price of approximately $2.60 per ADS), subject to adjustment in certain circumstances. The exchange is expected to close on May 20, 2014, subject to customary closing conditions.

Downgrade Alert for Amarin (AMRN)
Comtex SmarTrend(R) - Mon May 12, 7:11AM CDT
Amarin (NASDAQ:AMRN) was downgraded from Buy to Neutral at Citigroup today. The stock closed yesterday at $1.51 on volume of 2.4 million shares, above average daily volume of 1.8 million. Amarin Corporation PLC is a clinical-stage biopharmaceutical company. The Company researches, develops, and commercializes drugs for the treatment of hypertriglyceridemia, central nervous system disorders, and cardiovascular diseases.

Health Care Stocks to Watch Today: Amarin Corporation plc, Jazz Pharmaceuticals, and Vanda Pharmaceu
George Budwell, The Motley Fool - Motley Fool - Fri May 09, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Amarin ,  Jazz Pharmaceuticals and  Vanda Pharmaceuticals .   Amarin reports first-quarter earnings The much-maligned biotech Amarin reported...

Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations
GlobeNewswire - Fri May 09, 6:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2014, and provided an update on company operations.

Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
GlobeNewswire - Mon May 05, 8:41AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2014 financial results and provide an operational update on Friday, May 9, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's first quarter 2014 financial results earlier that day.

Amarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
GlobeNewswire - Fri May 02, 7:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa (icosapent ethyl) capsules significantly reduced apolipoprotein C-III (ApoC-III) levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride (TG) metabolism. This research is being presented today by Christie M. Ballantyne, M.D. from Baylor College of Medicine as part of a peer-reviewed poster session at the National Lipid Association Annual Scientific Sessions in Orlando, Florida.

Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at:

The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...

Amarin Corp. and Kowa Pharmaceuticals to Begin Joint Vascepa Promotion in May
ACCESSWIRE - Fri Apr 11, 11:25AM CDT
Amarin Corp. PLC (NASDAQ:AMRN) stock volume was tepid Apr. 10, with just 1,595,690 shares, a third of its three-month average volume of 4,405,235 shares.

More Trouble Looming for Amarin Corporation?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 1:30PM CDT
Amarin Corp. can't seem to catch a break these days. Almost immediately after inking a co-promotional deal for the company's lone commercial product, Vascepa, with Kowa Pharmaceuticals America, Teva Pharmaceuticals announced yesterday they are...

Partner Signed! Is Amarin's Turnaround Beginning?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Apr 06, 11:12AM CDT
Amarin has announced news long awaited by investors -- a partnership with a big pharma. Although the pharma itself is not a household name, Japan's Kowa Pharmaceuticals will essentially triple the sales force for Vascepa. Sales of the...

Can This Drive Growth for Amarin Corporation plc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 01, 1:30PM CDT
Small-cap biopharmaceutical Amarin has made it clear that the company is not giving up on Vascepa without a fight, several of them actually. In addition to challenging the FDA's decisions to rescind a Special Protocol Assessment (SPA) on the...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 78

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 461

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 343

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 317

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 442

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 522

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 247

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 259

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Valneva Faces Setback as Ixchiq Vaccine License Suspended

Updated Category News Views 213

Valneva SE's Ixchiq Vaccine Under Scrutiny Valneva SE stock (VALN) experienced a decline recently after the U.S. Food and Drug Administration (FDA) announced the suspension of its license for the Ixchiq vaccine. This decision stems from reports of serious adverse events (SAEs) linked to chikungunya-like illness, leading to concerns about the vaccine's safety profile....

Continue Reading
Tetra Tech Secures Major Water Management Deal Worth £800 Million

Updated Category News Views 114

Tetra Tech Selected for £800 Million Water Management Framework In a significant development, Tetra Tech, Inc. (NASDAQ: TTEK), a prominent provider of advanced consulting and engineering services, has been awarded a major contract by Northern Ireland Water. This framework agreement, valued at up to £800 million, aims to bolster the sustainable delivery of essential...

Continue Reading
Synedgen Secures $2.2 Million JWMRP Grant for MIIST305

Updated Category News Views 119

Synedgen Achieves Major Milestone with JWMRP Funding Synedgen, Inc., a prominent biotechnology firm, is making headlines with its recent announcement about receiving a substantial $2.2 million contract from the Joint Warfighter Medical Research Program (JWMRP). This funding is designated for the advancement of MIIST305, a pioneering therapeutic aimed at shielding...

Continue Reading
Ensurge Micropower ASA Expands Private Placement Opportunities

Updated Category News Views 210

Ensurge Micropower ASA Extends Private Placement Bookbuilding Ensurge Micropower ASA has recently made waves in the investment community with an update on its ongoing private placement. The company is taking strategic steps to extend the bookbuilding period, offering investors increased opportunities to participate. The update was shared following a stock exchange...

Continue Reading
Dale Hageman Takes Leadership Role as ESAC Board Chairman

Updated Category News Views 130

Dale Hageman to Lead ESAC Board as Chairman Spirit HR is proud to share that its CEO and Founder, Dale Hageman, has been elected Chairman of the Board for the Employer Services Assurance Corporation (ESAC). This leadership role reflects Dale’s long-standing dedication to the HR field and his steady commitment to the highest levels of financial assurance and...

Continue Reading